Organoselenocyanate-Conjugated NBDHEX Derivatives as Potent Anticancer Agents for the Treatment of Breast Cancer via ROS-Regulated Signaling Pathways.

Estrogen receptor-positive (ER+) breast cancer is the predominant subtype of breast cancer, having significant therapeutic drawbacks, largely driven by undesired toxicity and drug resistance associated with conventional treatment regimens. Conjugatin…

Preview only. Read the full abstract at the source